A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate
release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD).
Secondary Objectives:
To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD.
To compare the efficacy of IPX203 with IR CD-LD following multiple doses.
To evaluate the safety of IPX203.
Phase:
Phase 2
Details
Lead Sponsor:
IMPAX Laboratories, Inc. Impax Laboratories, LLC
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa